Last reviewed · How we verify

CJ-30001/CJ-30002 — Competitive Intelligence Brief

CJ-30001/CJ-30002 (CJ-30001/CJ-30002) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual GLP-1/GCG receptor agonist. Area: Endocrinology/Diabetes.

phase 3 Dual GLP-1/GCG receptor agonist GLP-1 receptor, Glucagon receptor Endocrinology/Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

CJ-30001/CJ-30002 (CJ-30001/CJ-30002) — HK inno.N Corporation. CJ-30001/CJ-30002 is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon receptors to improve glycemic control and promote weight loss.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CJ-30001/CJ-30002 TARGET CJ-30001/CJ-30002 HK inno.N Corporation phase 3 Dual GLP-1/GCG receptor agonist GLP-1 receptor, Glucagon receptor
VK2735 VK2735 Viking Therapeutics, Inc. phase 3 Dual GLP-1/GCG receptor agonist GLP-1R, GCGR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual GLP-1/GCG receptor agonist class)

  1. HK inno.N Corporation · 1 drug in this class
  2. Viking Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CJ-30001/CJ-30002 — Competitive Intelligence Brief. https://druglandscape.com/ci/cj-30001-cj-30002. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: